NeuroOne Medical Technologies Corporation Q3 2025 Earnings Call Transcript: Financial Progress and Product Advancements

NeuroOne Medical Technologies Corporation reported Q3 2025 financial results, with product revenue increasing 53% YoY to $7.1M. CEO Dave Rosa highlighted progress on financial objectives and successful patient outcomes with the OneRF ablation system, as well as advancements in product development programs and strengthening of the management team.

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) reported robust financial results for the third quarter of fiscal year 2025, highlighting significant growth and operational milestones. The company's product revenue surged 53% year-over-year (YoY) to $7.1 million, marking a substantial increase from the $4.6 million reported in the same quarter of the previous year [1].

CEO Dave Rosa emphasized the company's progress toward financial objectives and the successful outcomes achieved with the OneRF ablation system. The first patient treated with the OneRF ablation system has maintained one-year seizure freedom, significantly improving the patient's quality of life. This success underscores the potential of NeuroOne's technology to address debilitating neurological disorders.

In addition to the OneRF ablation system, NeuroOne made strides in expanding its market opportunities. The company submitted its 510(k) application for the OneRF Trigeminal Nerve Ablation System to the FDA, positioning itself to generate revenues from trigeminal nerve ablation in 2025. Furthermore, NeuroOne received the first order for its sEEG-based drug delivery system from a major biopharmaceutical company, indicating growing interest in its innovative solutions.

Operational highlights also included the receipt of 17 patents and the USPTO allowance for a key manufacturing patent, strengthening NeuroOne's intellectual property portfolio. The company also initiated efforts to prepare for international market entry by launching a program to apply for ISO 13485 certification.

The company's financial guidance for fiscal year 2025 was adjusted to reflect the increased revenue and gross margin expectations. NeuroOne expects product revenue to range between $8.0 million and $10.0 million, representing a 132% to 190% increase over the previous year. The company also raised its gross margin expectations to between 50% and 53%.

NeuroOne completed an oversubscribed $8.2 million capital raise in April 2025, securing funding through fiscal year 2026. This capital infusion has bolstered the company's financial position and provided a clearer path to potential profitability.

The company's net loss for the first nine months of fiscal year 2025 improved significantly, decreasing to $2.0 million from $9.0 million in the same period of the previous year. This improvement was driven by increased revenue and reduced operating expenses.

NeuroOne's management team will host an investor conference call and webcast on Thursday, August 14, 2025, at 8:30 a.m. Eastern time to discuss the third quarter fiscal year 2025 financial results and provide a corporate update.

References:
[1] https://www.stocktitan.net/news/NMTC/neuro-one-reports-third-quarter-fiscal-year-2025-financial-results-dvi9dpta2uqr.html